Mineralocorticoid receptor blockade for renoprotection.
作者信息
Cha Dae Ryong
机构信息
Division of Nephrology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.
出版信息
Kidney Res Clin Pract. 2018 Sep;37(3):183-184. doi: 10.23876/j.krcp.2018.37.3.183. Epub 2018 Sep 30.
Abstract
摘要
相似文献
1
Mineralocorticoid receptor blockade for renoprotection.
Kidney Res Clin Pract. 2018 Sep;37(3):183-184. doi: 10.23876/j.krcp.2018.37.3.183. Epub 2018 Sep 30.
2
Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuria-A Path for Improved Renoprotection?
Am J Med Sci. 2018 May;355(5):407-408. doi: 10.1016/j.amjms.2018.01.012. Epub 2018 Feb 7.
3
Acetate causes renoprotection like androgen and mineralocorticoid receptors blockade in testosterone-exposed pregnant rats.
Mol Cell Biochem. 2021 Apr;476(4):1861-1870. doi: 10.1007/s11010-020-04031-y. Epub 2021 Jan 21.
4
Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies--the effect on podocytes.
Nephrol Dial Transplant. 2009 Dec;24(12):3640-51. doi: 10.1093/ndt/gfp371. Epub 2009 Aug 8.
5
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.
Am J Physiol Renal Physiol. 2007 Jan;292(1):F131-9. doi: 10.1152/ajprenal.00147.2006. Epub 2006 Jul 11.
6
Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges.
Int J Mol Sci. 2023 Apr 23;24(9):7719. doi: 10.3390/ijms24097719.
7
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Am J Physiol Renal Physiol. 2009 Sep;297(3):F802-8. doi: 10.1152/ajprenal.00197.2009. Epub 2009 Jun 17.
8
Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
Eur J Pharmacol. 2002 Feb 2;436(3):207-16. doi: 10.1016/s0014-2999(01)01586-2.
9
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Eur J Intern Med. 2014 Feb;25(2):173-6. doi: 10.1016/j.ejim.2013.11.007. Epub 2013 Dec 4.
10
Recent advances in the pharmacotherapeutic management of diabetic kidney disease.
Expert Opin Pharmacother. 2022 May;23(7):791-803. doi: 10.1080/14656566.2022.2054699. Epub 2022 May 6.
引用本文的文献
1
Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis.
Diabetes Ther. 2023 Feb;14(2):415-424. doi: 10.1007/s13300-022-01359-0. Epub 2022 Dec 25.
本文引用的文献
1
Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis.
Kidney Res Clin Pract. 2018 Sep;37(3):257-265. doi: 10.23876/j.krcp.2018.37.3.257. Epub 2018 Sep 30.
2
An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.
Am J Transl Res. 2016 Mar 15;8(3):1339-54. eCollection 2016.
3
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.
4
Aldosterone antagonists for preventing the progression of chronic kidney disease.
Cochrane Database Syst Rev. 2014 Apr 29(4):CD007004. doi: 10.1002/14651858.CD007004.pub3.
5
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
Eur Heart J. 2013 Aug;34(31):2453-63. doi: 10.1093/eurheartj/eht187. Epub 2013 May 27.
6
Recovery from ischemic acute kidney injury by spironolactone administration.
Nephrol Dial Transplant. 2012 Aug;27(8):3160-9. doi: 10.1093/ndt/gfs014. Epub 2012 Apr 19.
7
Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.
Clin Exp Nephrol. 2010 Aug;14(4):303-14. doi: 10.1007/s10157-010-0298-8. Epub 2010 Jun 9.
8
Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease.
Nat Med. 2008 Dec;14(12):1370-6. doi: 10.1038/nm.1879. Epub 2008 Nov 23.
9
The incidence and implications of aldosterone breakthrough.
Nat Clin Pract Nephrol. 2007 Sep;3(9):486-92. doi: 10.1038/ncpneph0575.
10
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.
Kidney Int. 2003 May;63(5):1791-800. doi: 10.1046/j.1523-1755.2003.00929.x.
Zotero 插件